IgAN/FSGS Monitoring Roundtable | Q2 2026
This educational material was developed by independent expert faculty. Sponsors providing unrestricted educational support had no role in faculty selection, content development, conclusions, or dissemination.
Practical frameworks for monitoring cadence tradeoffs (frequency, patient burden, cost, actionable yield) and evaluation decision points in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).
Covers: what monitoring changes should trigger additional testing, closer follow-up, or escalation of evaluation, and what patterns typically do not warrant escalation. This material does not provide treatment recommendations.
Content forthcoming
Expected ~30 days post-session